# KEYVIBE-006 (NCT05298423)

> Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab/vibostolimab
- Indication: unresectable stage III non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05298423
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: pembrolizumab/vibostolimab; durvalumab; cisplatin; pemetrexed; etoposide; carboplatin; paclitaxel; thoracic radiotherapy
- Enrollment: 610
- Primary outcome: Number of Participants Who Experience at Least One Adverse Event (AE)
- Primary outcome: Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

## Indexed commentary on KEYVIBE-006 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keyvibe-006-nct05298423